Phase 3
Completed N=71
Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery
Kidney Failure, Acute
Source: ClinicalTrials.gov NCT00654992 ↗
Enrolled (actual)
71
Serious AEs
—
Results posted
Jun 2009
Primary outcomePrimary: Number of Participants Who Had AKI (Acute Kidney Injury) — 3; 10 participants
Summary
The purpose of this study is to determine whether erythropoietin is effective in preventing acute kidney dysfunction after coronary artery bypass grafting surgery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Had AKI (Acute Kidney Injury) |
3; 10 | — |
| SECONDARY Change in Estimated Glomerular Filtration Rate (eGFR) |
-1.5; -9.1 | — |
Eligibility Criteria
Inclusion Criteria
- Patients scheduled for elective CABG over age 18
Exclusion Criteria
- Under age 18
- Emergent CABG
- Prior exposure to nephrotoxic drug
- Dialysis patients
- Uncontrolled hypertension
Data sourced from ClinicalTrials.gov (NCT00654992). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.